<DOC>
	<DOCNO>NCT01463891</DOCNO>
	<brief_summary>To investigate clinical safety effectiveness eribulin mesylate patient inoperable recurrent breast cancer</brief_summary>
	<brief_title>Post-marketing Surveillance Clinical Safety Effectiveness Eribulin Mesylate Patients With Inoperable Recurrent Breast Cancer ( Study HAL01S )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Inoperable breast cancer Recurrent breast cancer Exclusion criterion : Corresponding contraindication eribulin mesylate Not applicable indication eribulin mesylate Not applicable aggravation recurrence breast cancer patient previously treat anthracycline and/or taxane antitumor drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>inoperable recurrent breast cancer</keyword>
</DOC>